Zacks Research Brokers Reduce Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research dropped their Q2 2026 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Tuesday, March 31st. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($0.02) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at $0.21 EPS and Q1 2028 earnings at $0.14 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million.

Other equities research analysts have also issued reports about the company. Citizens Jmp raised their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Friday, March 13th. Needham & Company LLC upped their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.60.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $2.61 on Thursday. The stock has a market capitalization of $670.27 million, a P/E ratio of -15.35, a P/E/G ratio of 1.97 and a beta of 1.17. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18. The business’s fifty day moving average is $3.08 and its two-hundred day moving average is $3.16.

Hedge Funds Weigh In On Esperion Therapeutics

Large investors have recently made changes to their positions in the business. AIGH Capital Management LLC acquired a new position in Esperion Therapeutics in the 3rd quarter valued at approximately $7,950,000. Royce & Associates LP acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at $6,078,000. Two Seas Capital LP boosted its stake in shares of Esperion Therapeutics by 43.6% during the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after buying an additional 3,024,104 shares during the period. Integral Health Asset Management LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $3,975,000. Finally, Quantbot Technologies LP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter valued at $476,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.